Zaryouh H - Search Results

1

Establishment of head and neck squamous cell carcinoma mouse models for cetuximab resistance and sensitivity.

Zaryouh H, De Pauw I, Baysal H, Melis J, Van den Bossche V, Hermans C, Lau HW, Lambrechts H, Merlin C, Corbet C, Peeters M, Vermorken JB, De Waele J, Lardon F, Wouters A. Zaryouh H, et al. Cancer Drug Resist. 2023 Oct 17;6(4):709-728. doi: 10.20517/cdr.2023.62. eCollection 2023. Cancer Drug Resist. 2023. PMID: 38239393 Free PMC article.

2

Co-Targeting the EGFR and PI3K/Akt Pathway to Overcome Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma: What about Autophagy?

Zaryouh H, Van Loenhout J, Peeters M, Vermorken JB, Lardon F, Wouters A. Zaryouh H, et al. Cancers (Basel). 2022 Dec 12;14(24):6128. doi: 10.3390/cancers14246128. Cancers (Basel). 2022. PMID: 36551613 Free PMC article.

3

The prognostic impact of the immune signature in head and neck squamous cell carcinoma.

Baysal H, Siozopoulou V, Zaryouh H, Hermans C, Lau HW, Lambrechts H, Fransen E, De Pauw I, Jacobs J, Peeters M, Pauwels P, Vermorken JB, Smits E, Lardon F, De Waele J, Wouters A. Baysal H, et al. Among authors: zaryouh h. Front Immunol. 2022 Oct 4;13:1001161. doi: 10.3389/fimmu.2022.1001161. eCollection 2022. Front Immunol. 2022. PMID: 36268020 Free PMC article.

4

Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine.

Van den Bossche V, Zaryouh H, Vara-Messler M, Vignau J, Machiels JP, Wouters A, Schmitz S, Corbet C. Van den Bossche V, et al. Among authors: zaryouh h. Drug Resist Updat. 2022 Jan;60:100806. doi: 10.1016/j.drup.2022.100806. Epub 2022 Jan 25. Drug Resist Updat. 2022. PMID: 35121337 Review.

5

The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An In Vitro Study on a Novel Combination Strategy.

Zaryouh H, De Pauw I, Baysal H, Pauwels P, Peeters M, Vermorken JB, Lardon F, Wouters A. Zaryouh H, et al. Front Oncol. 2021 Sep 10;11:697967. doi: 10.3389/fonc.2021.697967. eCollection 2021. Front Oncol. 2021. PMID: 34568028 Free PMC article.

6

The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies.

Baysal H, De Pauw I, Zaryouh H, Peeters M, Vermorken JB, Lardon F, De Waele J, Wouters A. Baysal H, et al. Among authors: zaryouh h. Front Immunol. 2021 Sep 7;12:737311. doi: 10.3389/fimmu.2021.737311. eCollection 2021. Front Immunol. 2021. PMID: 34557197 Free PMC article. Review.

7

Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR-targeting agents to treat head and neck squamous cell carcinoma.

Zaryouh H, De Pauw I, Baysal H, Peeters M, Vermorken JB, Lardon F, Wouters A. Zaryouh H, et al. Med Res Rev. 2022 Jan;42(1):112-155. doi: 10.1002/med.21806. Epub 2021 Apr 29. Med Res Rev. 2022. PMID: 33928670 Review.

8

Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status.

Baysal H, De Pauw I, Zaryouh H, De Waele J, Peeters M, Pauwels P, Vermorken JB, Smits E, Lardon F, Jacobs J, Wouters A. Baysal H, et al. Among authors: zaryouh h. Br J Cancer. 2020 Sep;123(5):752-761. doi: 10.1038/s41416-020-0934-3. Epub 2020 Jun 16. Br J Cancer. 2020. PMID: 32541873 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8 results

Search Page

Filters